

Elizabeth A. Golden, PA-C

Dawes Fretzin Clinical Research Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030
Fax (317) 516-5031
E-mail: elizabethdfcrg@gmail.com

Dawes Fretzin Dermatology Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Finch University of Health Sciences, Chicago Medical School, (North Chicago, IL)
Masters of Science in Physician Assistant Practice, 2002

University of Wisconsin-La Crosse, College of Science (La Crosse, WI)
Bachelor of Science in Microbiology with Chemistry minor, 2000

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Sub-Investigator, 2007-Present


Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Physician Assistant, 2007-Present

Community Orthocare (Anderson, IN)
Physician Assistant, 2004-2007

Dr. Robert Gallee and Associates (Geneva, IL)
Physician Assistant, 2002-2004

License/Certifications

Indiana State Physician Assistant License 10000674A
NCCPA 105400
NCCPA PA surgical boards, special recognition, 2002
CPR/AED Certified
ACLS Certified
Certified Nursing Assistant
Emergency Medical Technician
CITI GCP Certification



6-17-26

Elizabeth A. Golden, PA-C

Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Novum	70608502	Acne	Sub-I	2	03-Sep-08
Stiefel	W0261-301	Acne	Sub-I	3	22-Oct-09
Stiefel	W0260-301	Acne	Sub-I	3	18-Jan-11
Dow Pharma	DPSI-IDP-107-P2-02	Acne	Sub-I	2	14-Jun-11
Cipher	ISOCT.08.01	Acne	Sub-I	3	18-Oct-11
Warner Chilcott	PR-10411	Acne	Sub-I	2	09-Jan-13
Taro	CLBG1210	Acne	Sub-I	3	04-Feb-14
Cipher	RAN.13.01	Acne	Sub-I	3	13-Mar-14
Allergan	225678-007	Acne	Sub-I	3	21-Jan-15
Valeant	V01-123A-501	Acne	Sub-I	1b	14-Mar-17
Foamix	FX2014-05	Acne	Sub-I	3	27-Apr-17
Valeant	V01-121A-302	Acne	Sub-I	3	09-May-17
Elorac	EL-1006-01-01	Acne	Sub-I	2	06-Jun-17
Ranbaxy	ABS1517LT	Acne	Sub-I	4	24-Apr-18
Dr. Reddy's	DFD-03-CD-006	Acne	Sub-I	2	31-Jul-18
Foamix	FX2017-22	Acne	Sub-I	2	28-Sep-18
Bausch Health	V01-121A-501	Acne	Sub-I	1b	01-Oct-19
Bausch Health	V01-121A-302	Acne	Sub-I	3	01-Mar-21
UPENN	Acne	Acne	Sub-I	4	16-Apr-25
Sanofi	VBE00001	Acne	Sub-I	1/2	24-Feb-26
Aczone	225678-007	Acne	Sub-I	3	01-Mar-16
Peplin	PEP005-016	Actinic Keratosis	Sub-I	3b	07-Jan-10
Peplin	PEP005-028	Actinic Keratosis	Sub-I	3b	21-Jan-10
Peplin	PEP005-020	Actinic Keratosis	Sub-I	3b	26-Mar-10
Peplin	PEP005-030	Actinic Keratosis	Sub-I	3b	11-Jan-11
Peplin	PEP005-032	Actinic Keratosis	Sub-I	3b	11-Jan-11
Actavis	094-3153-301	Actinic Keratosis	Sub-I	4	11-Jun-14
LEO	LP0105-1012	Actinic Keratosis	Sub-I	1/2	13-Aug-14
LEO	LP0084-1148	Actinic Keratosis	Sub-I	2	15-Sep-15
Perrigo	PRG-NY-14-019	Actinic Keratosis	Sub-I	3	14-Dec-15
Actavis	094-8151-301	Actinic Keratosis	Sub-I	4	17-Dec-15
Actavis	094-8152-301	Actinic Keratosis	Sub-I	4	22-May-17
LEO	LP0105-1032	Actinic Keratosis	Sub-I	3	13-Oct-17
Athenex	KX01-AK-004	Actinic Keratosis	Sub-I	3	21-Nov-19
Merck	A-11107	Allergen Immunotherapy	Sub-I	OBS	09-Apr-13
Pfizer	B7931005	Alopecia Areata	Sub-I	2a	12-Mar-19
DRG Abacus	7785	Alopecia Areata	Sub-I	OBS	01-Sep-19
Evidera	EVA-20417-00	Alopecia Areata	Sub-I	OBS	11-Mar-20
Pfizer	B7981015	Alopecia Areata	Sub-I	2b/3	03-Aug-21
Reystone	RSJ10521	Alopecia Areata	Sub-I	2	26-Aug-21
AnaptysBio	ANB030-201	Alopecia Areata	Sub-I	2	22-Mar-23
Horizon	HZNP-DAX-201	Alopecia Areata	Sub-I	2a	28-Mar-23

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Concert	CP543.3001	Alopecia Areata	Sub-I	3	13-Jul-23
Arena	APD334-205	Alopecia Areata	Sub-I	2	30-Aug-23
Pfizer	B7981031	Alopecia Areata	Sub-I	1	17-Oct-23
Inmagene	IMG-007-002	Alopecia Areata	Sub-I	1b/2a	28-Jun-24
Pfizer	B7981032	Alopecia Areata	Sub-I	3	01-Aug-24
Aslan	ASLAN003-004	Alopecia Areata	Sub-I	2a	12-Aug-24
Sanofi	DRI18180	Alopecia Areata	Sub-I	2	10-Feb-25
Lilly	I4V-MC-JAIR	Alopecia Areata	Sub-I	3	13-Mar-25
Adelphi	AG9909	Alopecia Areata	Sub-I	OBS	15-Apr-26
Concert	CP543.5001	Alopecia Areata	Sub-I	3	28-Apr-26
DrenBio	DR-01-AIM-001	Alopecia Areata	Sub-I	1b	ONGOING
HCW Biologics	HCWALO101	Alopecia Areata	Sub-I	1b	ONGOING
Lilly	I4V-MC-JAIO	Alopecia Areata	Sub-I	3	ONGOING
Sun Pharma	CP543.3101	Alopecia Areata	Sub-I	3	ONGOING
Abbvie	M24-725	Alopecia Areata	Sub-I	3	ONGOING
CorEvitas	AA-565	Alopecia Areata	Sub-I	OBS	ONGOING
Pfizer	B7981027	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981028	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981094	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981110	Alopecia Areata	Sub-I	3	ONGOING
Pelage	PP405-2001	Androgenetic Alopecia	Sub-I	2a	24-Nov-25
Pelage	PP405-2002	Androgenetic Alopecia	Sub-I	2/3	ONGOING
Veradermics	250-13951-302	Androgenetic Alopecia	Sub-I	3	ONGOING
Veradermics	250-13951-306	Androgenetic Alopecia	Sub-I	3	ONGOING
GSK	SAS115358	Asthma	Sub-I	4	30-Oct-13
GSK	SAS115359	Asthma	Sub-I	4	01-May-14
Taro	TACR-0707	Atopic Dermatitis	Sub-I	2	12-May-09
Astellas	FHI-03-0-161/FG-506-06-37	Atopic Dermatitis	Sub-I	2	01-Oct-12
Anacor	AN2728-AD-203	Atopic Dermatitis	Sub-I	2a	21-Jan-13
Novartis	CBPR277X2101	Atopic Dermatitis	Sub-I	1	13-Feb-13
Anacor	AN2728-AD-302	Atopic Dermatitis	Sub-I	3	11-Aug-15
Anacor	AN2728-AD-303	Atopic Dermatitis	Sub-I	3	11-Nov-15
Regeneron	R668-AD-1314	Atopic Dermatitis	Sub-I	2	10-Dec-15
Regeneron	R668-AD-1334	Atopic Dermatitis	Sub-I	3	31-May-16
MedImmune	D5240C00001	Atopic Dermatitis	Sub-I	2a	22-Sep-16
Chugai	CIM003JG	Atopic Dermatitis	Sub-I	2	20-Oct-16
Regeneron	R668-AD-1415	Atopic Dermatitis	Sub-I	3	08-Feb-17
GSK	203121	Atopic Dermatitis	Sub-I	2	29-Mar-17
Pfizer	B7451006	Atopic Dermatitis	Sub-I	2b	26-Apr-17
Regeneron	R668-AD-1225	Atopic Dermatitis	Sub-I	3	27-Sep-17
LEO	LP0156-1294	Atopic Dermatitis	Sub-I	OBS	24-Oct-17
GSK	205050	Atopic Dermatitis	Sub-I	2a	11-Jan-18
Sun Pharma	71542612	Atopic Dermatitis	Sub-I	3	15-Feb-18

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Regeneron	R668-AD-1607	Atopic Dermatitis	Sub-I	1b	10-Apr-18
Incyte	INCB18424-206	Atopic Dermatitis	Sub-I	2	18-May-18
Novan	NI-AD101	Atopic Dermatitis	Sub-I	1b	25-Jun-18
Regeneron	R668-AD-1526	Atopic Dermatitis	Sub-I	3	19-Jul-18
Dermavant	RVT-502-2001	Atopic Dermatitis	Sub-I	2	01-Aug-18
Dermavant	RVT-501-2007	Atopic Dermatitis	Sub-I	1b	03-Aug-18
Pfizer	C0341001	Atopic Dermatitis	Sub-I	1	09-Oct-18
Lilly	I4V-MC-JAHL	Atopic Dermatitis	Sub-I	3	06-Dec-18
Pfizer	B7451012	Atopic Dermatitis	Sub-I	3	23-May-19
Pfizer	B7451013	Atopic Dermatitis	Sub-I	3	27-Jun-19
Dermira	DRM06-AD01	Atopic Dermatitis	Sub-I	2b	30-Jul-19
Kiniksa	KPL-716-C001	Atopic Dermatitis	Sub-I	1b	20-Sep-19
Asana	ASN002AD-201	Atopic Dermatitis	Sub-I	2b	25-Sep-19
LEO	LP0162-1326	Atopic Dermatitis	Sub-I	3	15-Oct-19
Galapagos	MOR106-CL-204	Atopic Dermatitis	Sub-I	2	28-Oct-19
Arcutis	ARQ-151-212	Atopic Dermatitis	Sub-I	2	10-Dec-19
Qurient	Q301-AD-P2-US002	Atopic Dermatitis	Sub-I	2	07-Jan-20
Ralexar	ALX-101-ATOP-204	Atopic Dermatitis	Sub-I	2	27-Jan-20
Asana	ASN002AD-201-EXT	Atopic Dermatitis	Sub-I	2	10-Mar-20
Pfizer	B7451036	Atopic Dermatitis	Sub-I	3	21-May-20
LEO	LP0133-1181	Atopic Dermatitis	Sub-I	1	25-Jun-20
Lilly	I4V-MC-JAIW	Atopic Dermatitis	Sub-I	3	03-Aug-20
Lilly	I4V-MC-JAIX	Atopic Dermatitis	Sub-I	3	03-Aug-20
Kyowa Hakko Kirin	4083-006	Atopic Dermatitis	Sub-I	2	15-Sep-20
Lilly	I4V-MC-JAHN	Atopic Dermatitis	Sub-I	3	21-Sep-20
Pfizer	B7451014	Atopic Dermatitis	Sub-I	3	19-Nov-20
Regeneron	R668-AD-1434	Atopic Dermatitis	Sub-I	3	09-Dec-20
Incyte	INCB18424-303	Atopic Dermatitis	Sub-I	3	28-Jan-21
Abbvie	M16-046	Atopic Dermatitis	Sub-I	3b	01-Feb-21
Xbiotech	2019-PT046	Atopic Dermatitis	Sub-I	2	21-Feb-21
Sanofi	LPS15496	Atopic Dermatitis	Sub-I	OBS	27-Apr-21
Sanofi	OBS15333	Atopic Dermatitis	Sub-I	OBS	27-Apr-21
Aclaris	ATI-1777-AD-201	Atopic Dermatitis	Sub-I	2a	23-Jun-21
Rapt	RPT193-01	Atopic Dermatitis	Sub-I	1	26-Jul-21
Pfizer	B7451050	Atopic Dermatitis	Sub-I	3b	12-Aug-21
BMX	BMX-DERM-01	Atopic Dermatitis	Sub-I	1/2	24-Aug-21
Pfizer	C3941002	Atopic Dermatitis	Sub-I	2a	15-Nov-21
Janssen	77474462ADM2003	Atopic Dermatitis	Sub-I	2a	06-Apr-22
Abbvie	M19-850	Atopic Dermatitis	Sub-I	3b	21-Apr-22
Janssen	77474462ADM2001	Atopic Dermatitis	Sub-I	3	16-May-22
Lilly	F1P-MC-KFAD	Atopic Dermatitis	Sub-I	1	21-Jun-22
BMS	IM011-005	Atopic Dermatitis	Sub-I	2	01-Aug-22
Dermira	DRM06-AD17	Atopic Dermatitis	Sub-I	3	24-Aug-22

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
BMS	IM018-005	Atopic Dermatitis	Sub-I	2	20-Sep-22
Celgene	CC-93538-AD-001	Atopic Dermatitis	Sub-I	2	07-Dec-22
Connect	CBP-201-WW004	Atopic Dermatitis	Sub-I	3	30-Dec-22
LEO	LP0162-1337	Atopic Dermatitis	Sub-I	3	27-Jan-23
Galderma	RD.06.SPR.118161	Atopic Dermatitis	Sub-I	3	13-Feb-23
GSK	215253	Atopic Dermatitis	Sub-I	1b	13-Jun-23
Arcutis	ARQ-151-313	Atopic Dermatitis	Sub-I	3	11-Jul-23
Pfizer	C3941005	Atopic Dermatitis	Sub-I	2b	01-Aug-23
OM1	DataDerm	Atopic Dermatitis	Sub-I	OBS	19-Aug-23
Evommune	EVO101-AD001	Atopic Dermatitis	Sub-I	2a	29-Aug-23
Alumis	ESK-001-006	Atopic Dermatitis	Sub-I	2	08-Sep-23
DermTech	20-03	Atopic Dermatitis	Sub-I	4	24-Oct-23
Acrotech	MEDI-MM36-301	Atopic Dermatitis	Sub-I	3	20-Nov-23
Evidera	EVA-25835	Atopic Dermatitis	Sub-I	OBS	15-Dec-23
Galderma	RD.06.SPR.118380	Atopic Dermatitis	Sub-I	2	21-Dec-23
Aslan	ASLAN004-003	Atopic Dermatitis	Sub-I	2b	04-Jan-24
Aclaris	ATI-1777-AD-202	Atopic Dermatitis	Sub-I	2b	06-Feb-24
Alumis	ESK-001-007	Atopic Dermatitis	Sub-I	2	13-Feb-24
TrialSpark	ASN008-201	Atopic Dermatitis	Sub-I	2	14-Feb-24
Cara	CR845-310501	Atopic Dermatitis	Sub-I	3	07-Mar-24
Kymab	KY1005-CT05	Atopic Dermatitis	Sub-I	2b	02-May-24
Rapt	RPT193-02	Atopic Dermatitis	Sub-I	2	07-Jun-24
Incyte	INCB18424-305	Atopic Dermatitis	Sub-I	3	26-Jun-24
Acrotech	MEDI-MM36-302	Atopic Dermatitis	Sub-I	3	16-Jul-24
Biosion	BSI-045B-002	Atopic Dermatitis	Sub-I	2a	18-Jul-24
Abbvie	M16-049	Atopic Dermatitis	Sub-I	2b	29-Oct-24
Abbvie	M23-696	Atopic Dermatitis	Sub-I	3b/4	29-Oct-24
Taro	RXLC-2118	Atopic Dermatitis	Sub-I	4	04-Dec-24
Incyte	INCB18424-902	Atopic Dermatitis	Sub-I	4	05-Feb-25
Pfizer	B7451015	Atopic Dermatitis	Sub-I	3	25-Mar-25
Lilly	J2T-MC-KGBO	Atopic Dermatitis	Sub-I	3b	01-Apr-25
Lilly	J2T-MC-KGBP	Atopic Dermatitis	Sub-I	3b	02-Apr-25
Dermira	DRM06-AD07	Atopic Dermatitis	Sub-I	3	09-Apr-25
Amgen	20210144	Atopic Dermatitis	Sub-I	3	29-Apr-25
Galderma	RD.06.SPR.118126	Atopic Dermatitis	Sub-I	2	11-Jun-25
Abbvie	M24-601	Atopic Dermatitis	Sub-I	3b/4	12-Jun-25
LEO	LP0145-2240	Atopic Dermatitis	Sub-I	2b	25-Jun-25
Apollo	AP43CP03	Atopic Dermatitis	Sub-I	2	04-Nov-25
CastleBio Science	CBI_2021_ISD_DevVal_001	Atopic Dermatitis	Sub-I	4	02-Dec-25
Galderma	RD.06.SPR.118163	Atopic Dermatitis	Sub-I	3	20-Jan-26
Sanofi	EFC17561	Atopic Dermatitis	Sub-I	3	03-Feb-26
Abbvie	M16-045	Atopic Dermatitis	Sub-I	3	04-Feb-26
Amgen	20210145	Atopic Dermatitis	Sub-I	3	26-Feb-26

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
TARGET-DERM	TARGET-DERM	Atopic Dermatitis	Sub-I	4	06-Apr-26
Janssen	95475939ADM2001	Atopic Dermatitis	Sub-I	2b	12-May-26
Roche	CS45943	Atopic Dermatitis	Sub-I	2	N/A
Attovia	ATTO-3712-101	Atopic Dermatitis	Sub-I	1	ONGOING
Enveda	ENV-294-202	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-B002	Atopic Dermatitis	Sub-I	4	ONGOING
Organon	OG0505-3104	Atopic Dermatitis	Sub-I	3	ONGOING
Triveni Bio	TRIV-509-101	Atopic Dermatitis	Sub-I	2a	ONGOING
Triveni Bio	TRIV-573-101	Atopic Dermatitis	Sub-I	2	ONGOING
Abbvie	M16-047	Atopic Dermatitis	Sub-I	3	ONGOING
Abbvie	M17-380	Atopic Dermatitis	Sub-I	3	ONGOING
Actaris	ATI-045-AD-201	Atopic Dermatitis	Sub-I	2b	ONGOING
Amgen	20210146	Atopic Dermatitis	Sub-I	3	ONGOING
Anacor	AN2728-AD-301-302-POST01	Atopic Dermatitis	Sub-I	OBS	ONGOING
Apogee	APG777-301	Atopic Dermatitis	Sub-I	3	ONGOING
Apollo	AP43CP04	Atopic Dermatitis	Sub-I	2b	ONGOING
CorEvitas	AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Corrona	Corrona-AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Galderma	SPR207806	Atopic Dermatitis	Sub-I	OBS	ONGOING
Janssen	95597528ADM2001	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-KGCE	Atopic Dermatitis	Sub-I	4	ONGOING
Pfizer	B7451023	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	B7451031	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	C4531002	Atopic Dermatitis	Sub-I	2	ONGOING
Pfizer	C4531005	Atopic Dermatitis	Sub-I	3	ONGOING
Roche	CS45570	Atopic Dermatitis	Sub-I	2	ONGOING
Sanofi	EFC17599	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	EFC17600	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	LTS17367	Atopic Dermatitis	Sub-I	2/3	ONGOING
Brickell	BBI-4000-CL-301	Axillary Hyperhidrosis	Sub-I	3	11-Aug-21
Akari	AK802	Bullous Pemphigoid	Sub-I	3	08-Sep-22
AstraZenaca	D325AC00002	Bullous Pemphigoid	Sub-I	3	31-Aug-23
Asana	ASN002AD-202	Chronic Hand Eczema	Sub-I	2	22-Jun-20
Arcutis	ARQ-252-205	Chronic Hand Eczema	Sub-I	1/2b	07-Aug-20
Evommune	EVO756-CIU001	Chronic Inducible Urticaria	Sub-I	2a	20-Jun-25
Celldex	CDX0159-07	Chronic Inducible Urticaria	Sub-I	2	25-Nov-25
Menlo	MTI-117	Chronic Pruritus of Unknown Origin	Sub-I	2	29-May-20
Sanofi	EFC16973	Chronic Pruritus of Unknown Origin	Sub-I	3	13-Nov-24
Novartis	CLOU064R12301	Chronic Pruritus of Unknown Origin	Sub-I	3	ONGOING
Galderma	SPR207913	Chronic Pruritus of Unknown Origin	Sub-I	2	ONGOING
Genentech	ACD4577g	Chronic Spontaneous Urticaria	Sub-I	2	10-Dec-09
Genentech	Q4882g	Chronic Spontaneous Urticaria	Sub-I	3	12-Sep-12
Novartis	CQGE031C2201	Chronic Spontaneous Urticaria	Sub-I	2b	29-Jun-16

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Genentech	ML29510	Chronic Spontaneous Urticaria	Sub-I	4	27-Jun-17
Novartis	CQGE031C2302	Chronic Spontaneous Urticaria	Sub-I	3	30-Sep-22
Novartis	CQGE031C2302E1	Chronic Spontaneous Urticaria	Sub-I	3b	25-Oct-22
Celldex	CDX0159-02	Chronic Spontaneous Urticaria	Sub-I	1	10-Jan-23
Evidera	EVA-32391-01	Chronic Spontaneous Urticaria	Sub-I	OBS	13-Mar-23
Amgen	20190194	Chronic Spontaneous Urticaria	Sub-I	2b	20-Apr-23
Celldex	CDX0159-06	Chronic Spontaneous Urticaria	Sub-I	2	07-Nov-23
Escient	EP-262-201	Chronic Spontaneous Urticaria	Sub-I	2	26-Mar-25
InflaRX	INF904-P2.1	Chronic Spontaneous Urticaria	Sub-I	2a	04-Dec-25
Blueprint Medicines	BLU-808-1201	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Celldex	CDX0159-12	Chronic Spontaneous Urticaria	Sub-I	3	ONGOING
Celldex	CDX0159-17	Chronic Spontaneous Urticaria	Sub-I	3b	ONGOING
Jasper Therapeutics	JSP-CP-011	Chronic Spontaneous Urticaria	Sub-I	2a	ONGOING
Jasper Therapeutics	JSP-CP-014	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Novartis	CLOU064AUS04	Chronic Spontaneous Urticaria	Sub-I	OBS	ONGOING
Novartis	CQAB149B2346	COPD	Sub-I	3	16-Dec-08
Novartis	CQAB149B2335S	COPD	Sub-I	3	16-Jan-09
Forest	LAS-MD-38	COPD	Sub-I	3b	23-Nov-10
Novartis	CQAB149B2341	COPD	Sub-I	3	16-Dec-10
GSK	HZA106837	COPD	Sub-I	3a	22-Nov-11
Novartis	CQVA149A2336	COPD	Sub-I	3	07-May-14
GSK	CTT116855	COPD	Sub-I	3	16-Jun-15
GSK	LPL100601	Coronary Heart Disease	Sub-I	3	13-Aug-13
Celgene	CC-11050-CLE-002	Cutaneous Lupus Erythematosus	Sub-I	2	01-Dec-12
Pfizer	A6261008	Cutaneous Lupus Erythematosus	Sub-I	3	26-Feb-14
Janssen	NOCOMPOUNDLUN0001	Cutaneous Lupus Erythematosus	Sub-I	OBS	29-Oct-14
Biogen	230LE201	Cutaneous Lupus Erythematosus	Sub-I	2	22-Jul-20
Gilead	GS-US-497-5888	Cutaneous Lupus Erythematosus	Sub-I	1b	29-Nov-22
Biogen	230LE301	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Biogen	230LE305	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Merck	MS200569-0003	Cutaneous Lupus Erythematosus	Sub-I	2	16-Jan-25
Horizon	HZNP-DAX-202	Cutaneous Lupus Erythematosus	Sub-I	2	21-Nov-25
Merck	MS200569-0048	Cutaneous Lupus Erythematosus	Sub-I	1	28-Jan-26
Gilead	GS-US-497-6486	Cutaneous Lupus Erythematosus	Sub-I	2a	19-May-26
Merck	MS504908_0008	Cutaneous Lupus Erythematosus	Sub-I	3	ONGOING
Ventus	VENT-03-201	Cutaneous Lupus Erythematosus	Sub-I	2a	ONGOING
Nflection	NFX-179-NFI-202	Cutaneous Neurofibroma	Sub-I	2	16-Oct-23
Regeneron	R2810-ONC-2251	Cutaneous Squamous Cell Carcinoma	Sub-I	3	28-May-26
CastleBio Science	CBI_2019_cSCC_PVS_001	Cutaneous Squamous Cell Carcinoma	Sub-I	4	ONGOING
Soligenix	HPN-CTCL-01	Cutaneous T-Cell Lymphoma	Sub-I	3	24-Feb-21
Elorac	EL-1007-01-01	Cutaneous T-Cell Lymphoma	Sub-I	3	20-Oct-22
Soligenix	HPN-CTCL-03-EUR	Cutaneous T-Cell Lymphoma	Sub-I	3	ONGOING
Lilly	F3Z-US-IOOV	Diabetes - Type 2	Sub-I	3	01-Oct-08

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Merck	079-00	Diabetes - Type 2	Sub-I	3	01-Oct-08
Takeda	TAK-875_306	Diabetes - Type 2	Sub-I	3	26-Feb-14
Lilly	H6D-MC-LVGO	Erectile Dysfunciton	Sub-I	3	21-Mar-06
Lilly	I4K-MC-GPEC	Erectile Dysfunciton	Sub-I	2	25-Jan-12
Evidera	EVA-16679	Genital Psoriasis	Sub-I	OBS	01-Jun-15
Lilly	I1F-MC-RHBQ	Genital Psoriasis	Sub-I	3	17-May-18
Celgene	CC-10004-PSOR-025	Genital Psoriasis	Sub-I	3	27-Apr-22
AnaptysBio	ANB019-002	GPP	Sub-I	2a	20-Oct-20
AnaptysBio	ANB019-401	GPP/PPP	Sub-I	3	02-Mar-23
Regeneron	R668-AD-1924	Hand/Foot Dermatitis	Sub-I	3	22-Feb-23
Lilly	J2T-MC-KGCD	Hand/Foot Dermatitis	Sub-I	3b	ONGOING
Lilly	I4J-MC-HHBA	Healthy Volunteers - Biomarkers	Sub-I	N/A	01-Jun-10
Pfarming	C1 1205-01	Hereditary Angioedema	Sub-I	2	07-May-10
Inhbitex	INH-FV1-005	Herpes Zoster	Sub-I	2	10-Dec-10
CSL Bering	CSI324-2001	Hidradenitis Suppurativa	Sub-I	2	10-May-14
AstraZenaca	D5440C00001	Hidradenitis Suppurativa	Sub-I	2a	10-Dec-14
Novartis	CCJM112X2202	Hidradenitis Suppurativa	Sub-I	2	29-Mar-17
Abbvie	H13-147	Hidradenitis Suppurativa	Sub-I	OBS	25-Feb-20
Xbiotech	2019-PT047	Hidradenitis Suppurativa	Sub-I	2	21-Feb-21
ChemoCentryx	CL016_168	Hidradenitis Suppurativa	Sub-I	2	11-May-21
Pfizer	C2501007	Hidradenitis Suppurativa	Sub-I	2a	15-Feb-22
Abbvie	M20-040	Hidradenitis Suppurativa	Sub-I	2	15-Mar-22
Boehringer Ingelheim	1368-0052	Hidradenitis Suppurativa	Sub-I	2a	29-Mar-22
Novartis	CAIN457M2302	Hidradenitis Suppurativa	Sub-I	2/3	31-Oct-22
Boehringer Ingelheim	1368-0067	Hidradenitis Suppurativa	Sub-I	2	31-Jan-23
Janssen	77474462HDS2001	Hidradenitis Suppurativa	Sub-I	2	10-Feb-23
Moonlake	M1095-HS-201	Hidradenitis Suppurativa	Sub-I	2	02-Oct-23
Acelyrin	21102	Hidradenitis Suppurativa	Sub-I	2	16-Apr-24
Acelyrin	22107	Hidradenitis Suppurativa	Sub-I	3	26-Feb-25
Adelphi	AB6762B	Hidradenitis Suppurativa	Sub-I	OBS	01-Mar-25
Boehringer Ingelheim	1368-0098	Hidradenitis Suppurativa	Sub-I	2b/3	31-Jul-25
Novartis	CAIN457M2301E1	Hidradenitis Suppurativa	Sub-I	3	26-Aug-25
Incyte	INCB54707-302	Hidradenitis Suppurativa	Sub-I	3	23-Jan-26
Incyte	INCB54707-301	Hidradenitis Suppurativa	Sub-I	3	17-Feb-26
Sanofi	ACT17841	Hidradenitis Suppurativa	Sub-I	2	19-Feb-26
Moonlake	M1095-HS-304	Hidradenitis Suppurativa	Sub-I	3	21-May-26
Incyte	INCB054707-801	Hidradenitis Suppurativa	Sub-I	3b	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-303	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Novartis	CCFZ533H12201BC	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Novartis	CLOU064J12301	Hidradenitis Suppurativa	Sub-I	3	ONGOING

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Abbvie	M20-262	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Abbvie	M20-465	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Abbvie	M23-698	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Lilly	I7P-MC-DSAF	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Merck	MK7240-012	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Pfizer	B7981119	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Novartis	SPP100A-2409	Hypertension	Sub-I	2	21-Jun-10
Mayne	18-ICH-001	Lamellar Ichthyosis	Sub-I	2	17-Jan-22
Timber	TMB01-301/MUST	Lamellar Ichthyosis	Sub-I	3	03-Dec-24
Priovant	PVT-2201-304	Lichen Planopilaris	Sub-I	2/3	ONGOING
Incyte	INCB18424-216	Lichen Planus	Sub-I	2	25-Apr-24
Novartis	CGIA362C12201	Lichen Planus	Sub-I	2	ONGOING
Lilly	I5V-MC-TSAT	Low Testosterone	Sub-I	3	25-Jun-15
Evidera	EVA-36509-01	Lower Abdominal Fat	Sub-I	OBS	08-Nov-23
Evidera	EVA-36509-02	Lower Abdominal Fat	Sub-I	OBS	18-Jul-24
Evidera	EVA-36509-04	Lower Abdominal Fat	Sub-I	OBS	23-Jan-25
Evidera	EVA-36509-08	Lower Abdominal Fat	Sub-I	OBS	18-Sep-25
Evidera	146323-01	Lower Abdominal Fat	Sub-I	OBS	01-Nov-25
Evidera	152364-01	Lower Abdominal Fat	Sub-I	OBS	01-Jun-26
Novan	NI-MC201	Molluscum Contagiosum	Sub-I	2	09-Jan-19
Novan	NI-MC301	Molluscum Contagiosum	Sub-I	3	09-Jan-19
DermTech	17-06	Multi-Indication	Sub-I	4	17-Jun-24
Novartis	CFTY720DUS01	Multiple Sclerosis	Sub-I	4	25-Jul-12
Lilly	I1F-MC-B018	Nail Psoriasis	Sub-I	OBS	29-Jan-25
Quoin	CL-QRX003-001	Netherton Syndrome	Sub-I	2	08-Apr-26
BioCryst	BCX17725-101	Netherton Syndrome	Sub-I	1	ONGOING
Quoin	CL-QRX003-002	Netherton Syndrome	Sub-I	2	ONGOING
Quoin	CL-QRX003-004	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-005	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-006	Netherton Syndrome	Sub-I	3	ONGOING
DermTech	21-02	Normal Skin	Sub-I	4	29-Jan-24
Mindera	MND-24-MK-02	Normal Skin	Sub-I	1	30-Sep-25
Evidera	EVA-27657	Notalgia Parasthetica	Sub-I	OBS	18-Mar-21
Cara	CR845-210601	Notalgia Parasthetica	Sub-I	2	11-Aug-22
Evidera	EVA-37056-00	Notalgia Parasthetica	Sub-I	OBS	24-Apr-24
Cara	CR845-310601	Notalgia Parasthetica	Sub-I	2-3	02-Jul-24
Clexio	CLE400-NP-201	Notalgia Parasthetica	Sub-I	2	24-Jan-25
Lilly	I1L-MC-GAEB	Obesity	Sub-I	2	16-Jul-10
Hisamitsu	HTU-520-US01	Onychomycosis	Sub-I	2	01-May-13
XOMA	X052160	Osteoarthritis of the Hand	Sub-I	2	10-Apr-14
XOMA	X052162	Osteoarthritis of the Hand	Sub-I	2	10-Apr-14
XOMA	X052161	Osteoarthritis of the Hand	Sub-I	2	01-Jun-15
Pfizer	A3191172	Osteoarthritis/Rheumatoid Arthritis	Sub-I	4	19-Sep-16

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Novartis	CAIN457A2312	Palmoplantar Psoriasis	Sub-I	3b	03-Apr-17
Abbvie	M15-994	Palmoplantar Psoriasis	Sub-I	3b	17-Jul-23
BMS	IM011-1112	Palmoplantar Psoriasis	Sub-I	4	02-Jul-25
AnaptysBio	ANB019-003	Palmoplantar Pustulosis	Sub-I	2	09-Jun-21
Aristea	RIST4721-202	Palmoplantar Pustulosis	Sub-I	2	12-May-23
Galderma	RD.06.SPR.18171	Papulopustular Rosacea	Sub-I	3	11-Sep-13
Cutanea	CLS001-CO-PR-001.01	Papulopustular Rosacea	Sub-I	2	17-Apr-14
Azitro	CTAR-403	Papulopustular Rosacea	Sub-I	1b/2a	10-Jun-21
Dr. Reddy's	DFD-29-CD-004	Papulopustular Rosacea	Sub-I	3	24-Jul-23
Evidera	EVA-20259	Pediatric Psoriasis	Sub-I	OBS	01-Oct-18
Sanofi	EFC16459	Prurigo Nodularis	Sub-I	3	25-May-22
Galderma	RD.06.SPR.202699	Prurigo Nodularis	Sub-I	3	13-Jun-22
Galderma	RD.06.SPR.203065	Prurigo Nodularis	Sub-I	3	13-Jun-22
Incyte	INCB18424-110	Prurigo Nodularis	Sub-I	1	09-May-25
InnoCare	ICP-CL-00609	Prurigo Nodularis	Sub-I	2	ONGOING
Sanofi	OBS17721	Prurigo Nodularis	Sub-I	4	ONGOING
Galderma	SPR207807	Prurigo Nodularis	Sub-I	OBS	ONGOING
Abbott	M05-736	Psoriasis	Sub-I	2	07-Jul-08
Centocor	C0743T12	Psoriasis	Sub-I	3	26-Feb-09
Abbott	M10-114	Psoriasis	Sub-I	3	15-Apr-09
Genzyme	HECTPS02507	Psoriasis	Sub-I	2	13-May-09
Abbott	M10-238	Psoriasis	Sub-I	3	09-Jul-09
Abbott	M06-890	Psoriasis	Sub-I	3	29-Jul-09
Genentech	ACD4412n	Psoriasis	Sub-I	4	20-Sep-09
Genentech	ACD3101g	Psoriasis	Sub-I	3b	07-Oct-09
Genentech	ACD3101g	Psoriasis	Sub-I	3b	07-Oct-09
Abbott	M03-658	Psoriasis	Sub-I	3	15-Oct-09
Celgene	CC-10004-PSOR-005	Psoriasis	Sub-I	2b	26-Jan-10
Lilly	I1F-MC-RHAG	Psoriasis	Sub-I	2	02-Jun-10
Lilly	I1X-MC-BDAD	Psoriasis	Sub-I	2	30-Jul-10
Celgene	CC-10004-PSOR-005E	Psoriasis	Sub-I	2b	11-Aug-10
Wyeth	3199K2-1105-US	Psoriasis	Sub-I	1	06-Dec-10
Novo-Nordisk	NN8226-1848	Psoriasis	Sub-I	1/2a	03-Mar-11
Amgen	20070559	Psoriasis	Sub-I	3	15-Mar-11
Centocor	C0743T08	Psoriasis	Sub-I	3	27-Jul-11
Wyeth	3226K1-1002-WW	Psoriasis	Sub-I	1	19-Sep-11
Centocor	C0743T09	Psoriasis	Sub-I	3	16-Dec-11
Abbott	M10-016	Psoriasis	Sub-I	3	06-Mar-12
Maruho	M518101-US01	Psoriasis	Sub-I	2b	07-Mar-12
Schering Plough	PO5495	Psoriasis	Sub-I	2	30-Jan-13
Amgen	20040210	Psoriasis	Sub-I	OBS	19-Feb-13
Amgen	20040210	Psoriasis	Sub-I	OBS	19-Feb-13
Lilly	I1F-MC-RHBL	Psoriasis	Sub-I	3	03-Oct-13

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Janssen	CNT01959PSO2001	Psoriasis	Sub-I	2	01-Nov-13
GSK	200851	Psoriasis	Sub-I	3	01-Dec-13
Pfizer	A3921078	Psoriasis	Sub-I	3	06-Jan-14
Amgen	HRA1889A	Psoriasis	Sub-I	OBS	20-Aug-14
Novartis	CAIN457A2223	Psoriasis	Sub-I	2	08-May-15
Celgene	CC-10004-PSOR-010	Psoriasis	Sub-I	3b	15-Jul-15
Pfizer	B7451005	Psoriasis	Sub-I	2	02-Sep-15
Maruho	M518101-US02	Psoriasis	Sub-I	3	11-Sep-15
Amgen	20120104	Psoriasis	Sub-I	3	22-Dec-15
Janssen	38515168PSO2001	Psoriasis	Sub-I	2	13-Jan-16
Novartis	CCJM112X2101	Psoriasis	Sub-I	1	26-Jan-16
Amgen	HRA1603A (20130126)	Psoriasis	Sub-I	OBS	11-Feb-16
Galderma	RD.06.SPR.18104	Psoriasis	Sub-I	4	25-Feb-16
Amgen	20101177	Psoriasis	Sub-I	4	18-Mar-16
Evidera	EVA-18225	Psoriasis	Sub-I	OBS	02-Jun-16
Tolmar	TOL2707A	Psoriasis	Sub-I	3	02-Jun-16
Janssen	CNT01959PSO3003	Psoriasis	Sub-I	3	19-Jul-16
Sandoz	GP17-301	Psoriasis	Sub-I	3	24-Jul-16
Evidera	EVA-18225-01	Psoriasis	Sub-I	OBS	03-Aug-16
Promius	DFD06-CD-005	Psoriasis	Sub-I	3	29-Aug-16
Celgene	CC-10004-PSOR-008	Psoriasis	Sub-I	3	06-Oct-16
Pfizer	A3921061	Psoriasis	Sub-I	3	11-Oct-16
Novartis	CAIN457A2317	Psoriasis	Sub-I	3b	19-Nov-16
Novartis	CAIN457A2313	Psoriasis	Sub-I	3b	04-Apr-17
Novartis	CAIN457A2303	Psoriasis	Sub-I	3	04-Apr-17
Amgen	20120363	Psoriasis	Sub-I	OBS	12-Apr-17
Lilly	I1F-MC-RHBP	Psoriasis	Sub-I	3	07-Jun-17
UCB	PS0010	Psoriasis	Sub-I	2b	12-Jun-17
BMS	IM011-011	Psoriasis	Sub-I	2	23-Aug-17
Stiefel	STF115750	Psoriasis	Sub-I	1	30-Aug-17
Janssen	CNT01275PSO3013	Psoriasis	Sub-I	3	05-Oct-17
Baxalta	911401	Psoriasis	Sub-I	3	24-Oct-17
Novartis	CAIN457A2304	Psoriasis	Sub-I	3	25-Oct-17
Novartis	CAIN457A2304E1	Psoriasis	Sub-I	3	25-Oct-17
Novartis	CAIN457A2302E1	Psoriasis	Sub-I	3	18-Nov-17
Boehringer Ingelheim	1311.28	Psoriasis	Sub-I	3	21-Nov-17
Sun Pharmaceuticals	71542611	Psoriasis	Sub-I	3	16-Feb-18
UCB	PS0003	Psoriasis	Sub-I	3	01-Apr-18
Pfizer	B7931004	Psoriasis	Sub-I	2a	08-May-18
Pfizer	B7931004	Psoriasis	Sub-I	2a	08-May-18
Allergan	1957-201-001	Psoriasis	Sub-I	2b	22-May-18
Galderma	RD.06.SPR.18131	Psoriasis	Sub-I	4	29-Aug-18
Novartis	CAIN457A2326	Psoriasis	Sub-I	3	26-Sep-18

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Janssen	CNT01959PSO3009	Psoriasis	Sub-I	3	30-Oct-18
Novartis	CAIN457A2310	Psoriasis	Sub-I	3	31-Oct-18
Boehringer Ingelheim	1297.9	Psoriasis	Sub-I	3	01-Jan-19
Lilly	I1F-MC-RHAZ	Psoriasis	Sub-I	3	23-Jan-19
Sienna	SNA-120-202	Psoriasis	Sub-I	2	01-Feb-19
Dermira	PS0003	Psoriasis	Sub-I	3	13-Mar-19
Dr. Reddy's	PPC-06-CD-004	Psoriasis	Sub-I	2	28-May-19
Novartis	CAIN457AUS07	Psoriasis	Sub-I	4	03-Jun-19
Lilly	I7P-MC-DSAB	Psoriasis	Sub-I	1	29-Aug-19
Lilly	I7P-MC-DSAB	Psoriasis	Sub-I	1	29-Aug-19
Kadmon	KD025-211	Psoriasis	Sub-I	2	07-Nov-19
Lilly	I1F-MC-RHBC	Psoriasis	Sub-I	3	17-Dec-19
Merck	MK3222-010	Psoriasis	Sub-I	3	28-Jan-20
Akros	AE451-G-18-004	Psoriasis	Sub-I	2/3	12-May-20
Dermavant	DMVT-505-3001	Psoriasis	Sub-I	3	22-Jul-20
Lilly	I6T-MC-AMAJ	Psoriasis	Sub-I	3	22-Jul-20
Lilly	I1F-MC-RHCR	Psoriasis	Sub-I	4	23-Jul-20
Janssen	CNT01959PSO3002	Psoriasis	Sub-I	3	10-Sep-20
Celgene	CC-10004-PSOR-022	Psoriasis	Sub-I	3	22-Oct-20
Novartis	CAIN457A2324	Psoriasis	Sub-I	3b	10-Nov-20
Arcutis	ARQ-154-204	Psoriasis	Sub-I	2b	02-Dec-20
BMS	IM011-047	Psoriasis	Sub-I	3	19-Jan-21
Arcutis	ARQ-151-302	Psoriasis	Sub-I	3	31-Mar-21
Arcutis	ARQ-151-306	Psoriasis	Sub-I	3	28-Apr-21
GSK	200853	Psoriasis	Sub-I	3	01-May-21
Dermavant	DMVT-505-3003	Psoriasis	Sub-I	2/3	08-Jun-21
Boehringer Ingelheim	1407-0030	Psoriasis	Sub-I	2	22-Jul-21
Lilly	I6T-MC-AMBK	Psoriasis	Sub-I	2/3	28-Jul-21
Boehringer Ingelheim	1407-0005	Psoriasis	Sub-I	2	21-Oct-21
Lilly	F1P-MC-KFAC	Psoriasis	Sub-I	1	03-Nov-21
Lilly	I6T-MC-AMAH	Psoriasis	Sub-I	3	28-Apr-22
Amgen	20190232	Psoriasis	Sub-I	3	08-Sep-22
Janssen	77242113PSO2001	Psoriasis	Sub-I	2b	28-Sep-22
Abbvie	M19-164	Psoriasis	Sub-I	3b	29-Sep-22
Abbvie	M19-164 Companion	Psoriasis	Sub-I	3b	29-Sep-22
Aurigene	AUR101-202	Psoriasis	Sub-I	2	12-Oct-22
Arcutis	ARQ-151-311	Psoriasis	Sub-I	3	08-Nov-22
Nimbus	4858-201	Psoriasis	Sub-I	2b	05-Dec-22
Biocon	BIO-USTEKI-305	Psoriasis	Sub-I	3	20-Dec-22
Janssen	77242113PSO2002	Psoriasis	Sub-I	2b	23-Jan-23
Abbvie	M15-997	Psoriasis	Sub-I	3	20-Mar-23
Abbvie	M18-816	Psoriasis	Sub-I	2	20-Mar-23
Abbott	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Abbott	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
PSOLAR	C0168Z03	Psoriasis	Sub-I	OBS	18-May-23
Abbvie	M20-326	Psoriasis	Sub-I	4	17-Jul-23
Celgene	CC-10004-PPSO-003	Psoriasis	Sub-I	3	03-Aug-23
Biocon	BM12H-PSO-03-G-02	Psoriasis	Sub-I	3	11-Jan-24
Ventyx	VTX958-201	Psoriasis	Sub-I	2	13-Feb-24
Janssen	77242113PSO3001	Psoriasis	Sub-I	3	19-Mar-24
DICE Therapeutics	DCE806201	Psoriasis	Sub-I	2	28-Mar-24
Mindera	MND-21-MKPs-02	Psoriasis	Sub-I	4	28-May-24
LITE	PCS-1608-35830	Psoriasis	Sub-I	2/3	05-Jul-24
UCB	PS0020	Psoriasis	Sub-I	2	17-Jul-24
Sanofi	DRI17849	Psoriasis	Sub-I	2	03-Dec-24
Janssen	77242113PSO3003	Psoriasis	Sub-I	3	14-Jan-25
Janssen	77242113PSO3002	Psoriasis	Sub-I	3	20-Feb-25
BMS	IM011-075	Psoriasis	Sub-I	3b	06-May-25
Janssen	CNT01959PSO3018	Psoriasis	Sub-I	3b	10-Sep-25
Takeda	TAK279-3001	Psoriasis	Sub-I	3	20-Jan-26
Alumis	ESK-001-016	Psoriasis	Sub-I	3	17-Feb-26
Dermavant	DMVT-505-3004	Psoriasis	Sub-I	3	11-Mar-26
Celgene	CC-10004-PPSO-004	Psoriasis	Sub-I	3b	24-Mar-26
Takeda	TAK-279-PsO-3004	Psoriasis	Sub-I	3	02-Jun-26
Abbvie	M24-541	Psoriasis	Sub-I	4	02-Jun-26
Alumis	ESK-001-018	Psoriasis	Sub-I	3	ONGOING
InventisBio	D2570-207	Psoriasis	Sub-I	2	ONGOING
Takeda	TAK279-3003	Psoriasis	Sub-I	3	ONGOING
Amgen	20200196	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1128	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1130	Psoriasis	Sub-I	3b/4	ONGOING
CorEvitas	CorEvitas-PSO-505	Psoriasis	Sub-I	OBS	ONGOING
Corrona	Corrona-PSO-550	Psoriasis	Sub-I	4	ONGOING
Lilly	I1F-MC-RHDC	Psoriasis	Sub-I	3b	ONGOING
Lilly	I1F-MC-RHDD	Psoriasis	Sub-I	3b	ONGOING
UCB	PS0021	Psoriasis	Sub-I	3	ONGOING
UPENN	CP3	Psoriasis	Sub-I	4	ONGOING
AbGenomics	2012.005.01	Psoriasis	Sub-I	2a	15-Apr-14
AbGenomics	2014.002.01	Psoriasis	Sub-I	2	09-Apr-15
Abcentra	ORT-2020-01	Psoriasis	Sub-I	2	21-Feb-23
Celgene	CC-10004-PSA-004	Psoriatic Arthritis	Sub-I	3	14-Dec-12
Janssen	CNT01275PSA3002	Psoriatic Arthritis	Sub-I	3	17-Jan-13
Janssen	CNT01275PSA3001	Psoriatic Arthritis	Sub-I	3	06-Aug-13
Janssen	CNT0148PSA3001	Psoriatic Arthritis	Sub-I	3	08-Sep-15
Janssen	CNT01959PSA2001	Psoriatic Arthritis	Sub-I	2a	01-Mar-17
Abbvie	H15-457	Psoriatic Arthritis	Sub-I	OBS	25-Oct-17

Elizabeth A. Golden, PA-C

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Janssen	CNT01959PSA3001	Psoriatic Arthritis	Sub-I	3	10-Jul-18
Janssen	CNT01959PSA3002	Psoriatic Arthritis	Sub-I	3	10-Jul-18
Novartis	CAIN457F2318	Psoriatic Arthritis	Sub-I	3	06-Sep-18
Novartis	CAIN457P12302	Psoriatic Arthritis	Sub-I	3	12-Sep-22
Nimbus	4858-202	Psoriatic Arthritis	Sub-I	2b	29-Mar-23
Novartis	CAIN457A02001B	Psoriatic Arthritis	Sub-I	4	23-Jan-25
Boehringer Ingelheim	1368-0140	Pyoderma Gangrenosum	Sub-I	3	ONGOING
Merck	MK-0663-107	Rheumatoid Arthritis	Sub-I	3	29-Jul-14
Perrigo	PRG-NY-14-022	Rosacea	Sub-I	3	17-Nov-15
Cutanea	CLS001-CO-PR-006	Rosacea	Sub-I	3	07-Mar-18
Galderma	GLI.04.SPR.US10120	Rosacea	Sub-I	4	01-Nov-09
Evidera	EVA-20371-01	Scalp Psoriasis	Sub-I	OBS	11-Jan-24
BMS	IM011-220	Scalp Psoriasis	Sub-I	3b/4	19-Nov-24
Arcutis	ARQ-154-304	Seborrheic Dermatitis	Sub-I	3	06-Jul-22
Lilly	F1K-US-EVDO	Sepsis	Sub-I	4	01-Oct-09
Evidera	EVA-44850	Skin Tone Assessment	Sub-I	OBS	ONGOING
Merck	009-00	Vaccine	Sub-I	2	26-Feb-13
RXI	RXI-SCP-1502	Verruca Vulgaris	Sub-I	2a	06-Sep-18
Incyte	INCB18424-211	Vitiligo	Sub-I	2	28-Aug-20
DRG Abacus	8493	Vitiligo	Sub-I	OBS	01-Dec-20
Evidera	EVA-31203-01	Vitiligo	Sub-I	OBS	31-Oct-22
Abbvie	M19-051	Vitiligo	Sub-I	2	09-Nov-23
Merck	MK-6194-007	Vitiligo	Sub-I	2a	20-May-25
VYNE	VY2024-02	Vitiligo	Sub-I	2b	30-Jul-25
Pfizer	B7981080	Vitiligo	Sub-I	3	10-Sep-25
Pfizer	B7981040	Vitiligo	Sub-I	3	05-Mar-26
Novartis	CGIA362B12201	Vitiligo	Sub-I	2	ONGOING
Abbvie	M19-044	Vitiligo	Sub-I	3	ONGOING
Abbvie	M25-264	Vitiligo	Sub-I	3	ONGOING
Lilly	J5D-MC-FPAD	Vitiligo	Sub-I	2	ONGOING
Pfizer	B7981041	Vitiligo	Sub-I	3	ONGOING
Aclaris	A-101-WART-202	Warts	Sub-I	2	11-Apr-18
Cutanea	CLS006-CO-PR-002	Warts	Sub-I	3	22-Jan-19
Aclaris	A-101-WART-301	Warts	Sub-I	3	26-Nov-19
Aclaris	A-101-WART-303	Warts	Sub-I	3	29-Jan-20